Shots:

• BMS acquires Celgene- in all stock transaction for $74B. Celgene to receive $50/share- 1 BMS share  and 1 Contingent Value Right (CVR) of $9 cash as regulatory milestone for each future approval of Celgene’s three drugs candidates ozanimod- liso-cel- bb2121
• Celgene has received premium value of 54% on its last day closing share price making it  $102.43/share. The focus of the acquisition is to expand its portfolio in Oncology- Immunology and Inflammation and Cardiovascular Disease. The transaction is expected to close in Q3’19
• Ozanimod is a P-III candidate indicated for relapsing multiple sclerosis and ulcerative colitis with its expected approval in 31 Dec- 2020. Lisocabtagene maraleucel (JCAR01- liso-cel) is a CD19-directed CAR T candidate indicated for r/r B cell lymphoma- primary mediastinal B-cell lymphoma- follicular lymphoma Grade 3B- and mantle cell lymphoma with expected approval in 31 Dec- 2020

Ref: BMS | Image: BMS